Literature DB >> 9613726

Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.

J H Kordower1, T B Freeman, E Y Chen, E J Mufson, P R Sanberg, R A Hauser, B Snow, C W Olanow.   

Abstract

We have previously demonstrated that fetal nigral grafts can survive, reinnervate the striatum, and mediate clinically relevant recovery in a patient with Parkinson's disease (PD). Most previous autopsy cases have failed to identify meaningful numbers of viable grafted cells suggesting that differences in critical transplant variables determine graft viability. The present study evaluated the structural and functional correlates of fetal nigral transplantation in a second PD patient who received fetal nigral grafts according to our previously published transplant protocol. A 61-year-old woman with severe PD received bilateral fetal nigral grafts to the postcommissural putamen from seven donor fetuses (four right side and three left side) aged 6.5-9 weeks postconception. This patient died 19 months after surgery from a cause unrelated to the transplant surgery. Her postoperative clinical course was characterized by improved motor and activities of daily living scores during "off time," reduced "off time," and increased "on" time without dyskinesia. Positron emission tomography (PET) scans revealed a bilateral and progressive increase in fluorodopa (FD) uptake within the grafted putamen. Postmortem examination of the right hemisphere revealed large oval-shaped grafts containing more than 138,000 tyrosine-hydroxylase-immunoreactive (TH-ir) neurons. Grafted cells formed a seamless border with the host and provided dense TH-ir innervation to 78% of the host postcommissural putamen. Graft-mediated sprouting of host fibers was not observed. These data provide essential confirmation that, under appropriate transplant conditions, grafted nigral neurons can survive, reinnervate the host striatum, and provide clinical benefit to PD patients. These findings also support the concept that improved motor function and striatal FD uptake on PET after nigral grafting in PD are the result of the viability of grafted neurons and graft-derived reinnervation of the host striatum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613726     DOI: 10.1002/mds.870130303

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  56 in total

1.  Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers.

Authors:  Brian A Aguado; Widya Mulyasasmita; James Su; Kyle J Lampe; Sarah C Heilshorn
Journal:  Tissue Eng Part A       Date:  2011-12-20       Impact factor: 3.845

Review 2.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 3.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

Review 4.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 5.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

6.  Two-component protein-engineered physical hydrogels for cell encapsulation.

Authors:  Cheryl T S Wong Po Foo; Ji Seok Lee; Widya Mulyasasmita; Andreina Parisi-Amon; Sarah C Heilshorn
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 7.  Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.

Authors:  Oliver Cooper; Arnar Astradsson; Penny Hallett; Harold Robertson; Ivar Mendez; Ole Isacson
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 8.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

9.  Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology.

Authors:  T B Freeman; F Cicchetti; R A Hauser; T W Deacon; X J Li; S M Hersch; G M Nauert; P R Sanberg; J H Kordower; S Saporta; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 10.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.